Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.63 |
| ▸ | AKT2 | P31751 | 20/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271134 | 0.93 | AKT1 (0.55) | AKT1AKT2KCNH2AKT3 | |
| SCHEMBL2277792 | 0.89 | AKT1 (0.54) | AKT1AKT2KCNH2AKT3 | |
| SCHEMBL25735884 | 0.87 | AKT1 (0.63) | AKT1AKT2AKT3 | |
| SCHEMBL3899104 | 0.87 | AKT1 (0.80) | AKT1AKT2KCNH2 | |
| SCHEMBL3903328 | 0.86 | AKT1 (0.77) | AKT1AKT2AKT3 | |
| SCHEMBL27056742 | 0.86 | AKT1 (0.61) | AKT1AKT2AKT3 | |
| SCHEMBL3902329 | 0.85 | AKT1 (0.77) | AKT1AKT2AKT3 | |
| SCHEMBL3889646 | 0.85 | AKT1 (0.77) | AKT1AKT2AKT3 | |
| SCHEMBL3188086 | 0.85 | AKT1 (0.50) | AKT1AKT2KCNH2AKT3 | |
| SCHEMBL2271586 | 0.85 | AKT1 (0.55) | AKT1AKT2KCNH2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544677-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | claimed |
| US-20070254901-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | claimed |
| US-7544677-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544677-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544677-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070254901-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254901-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254901-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254901-A1 | Inhibitors of Akt Activity | AKT1, AKT2, PIK3CD | AKT1 1/4885AKT2 2/4885KCNH2 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.